Needham Reiterates Trevi Therapeutics (TRVI) Buy Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on May 12, 2023, Needham reiterated coverage of Trevi Therapeutics (NASDAQ:TRVI) with a Buy recommendation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2182935548-c6af1cf197eb48bfb87d54bb4309912c.jpg "Trump Threatens 25% Import Tariffs on Mexico, Canada, Additional 10% on China")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1141453762-aa866db1b16b4a30837e1ec60aca1bff.jpg "Is Airbnb a Good Option for Las Vegas Visitors?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-931502252-a77507c63d7a4fd0a40757acd8c61bd8.jpg "Calculating the Payback Period With Excel")
:max_bytes(150000):strip_icc():format(jpeg)/how-to-get-dental-implants-covered-by-insurance-8580639-final-32bfbed60ccd4b7d9bd779c178672de5.png "How to Get Dental Implants Covered by Insurance")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1690944060-bfe2f518300d485e8962d425003e5c56.jpg "Ray Dalio Reveals How His Costliest Blunder Turned Into His Best Investing Lesson")